pharmaceuticals
pharmaceuticals Articles
Shares of Marinus Pharmaceuticals tumbled Monday morning after the company gave an update on top-line results from a Phase 3 clinical trial.
Published:
Last Updated:
Eleven Biotherapeutics watched its shares climb early on Monday morning following a key FDA submission.
Published:
Last Updated:
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
Published:
Last Updated:
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Published:
Last Updated:
Merck and Afferent Pharmaceuticals reportedly have signed a definitive agreement under which the former will acquire the latter.
Published:
Last Updated:
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
Selecta Biosciences expects to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Published:
Last Updated:
Janus Capital has now launched the Obesity ETF, which has a strategy of investing in companies that provide treatment and care for obesity and obesity‐related disease.
Published:
Last Updated:
Despite its track record, some analysts are calling for an inflection point, while others are taking a relatively neutral stance on Valeant Pharmaceuticals.
Published:
Last Updated:
Shares of Flexion Therapeutics dropped early on Wednesday following the announcement of an underwritten public offering.
Published:
Last Updated:
Valeant Pharmaceuticals International reported disappointing first-quarter financial results before the markets opened on Tuesday.
Published:
Last Updated:
inVentiv Group Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
Published:
Last Updated:
Some call the ASCO annual meeting the "Super Bowl for biotechs" because of the significance it holds for so many companies.
Published:
Last Updated: